The Health Sciences Authority (HSA) has approved Sanofi and AstraZeneca's BEYFORTUS (nirsevimab) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and ...

AstraZeneca chief executive Pascal Soriot is reportedly considering moving the company's stock exchange listing from the UK to the US.

AstraZeneca's light chain (AL) amyloidosis candidate anselamimab has failed a phase 3 readout, but showed efficacy in a patient subgroup.

Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and a broader hematology ...